CTOs on the Move

Top RX

www.toprx.com

 
If you think all generic pharmaceutical distributors are alike, it’s time to think again. We’re TOP RX, a leading national generic distributor that helps more than 5,000 pharmacies keep prices low on more than 2,800 generic pharmaceuticals. We call our company “TOP” for several reasons. We bring value to your business in many ways including our technological solutions, guaranteed product credibility and competitive pricing.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.toprx.com
  • 2950 Brother Boulevard
    Bartlett, TN USA 38133
  • Phone: 800.542.8677

Executives

Name Title Contact Details

Similar Companies

Alkermes

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

ADV-Care Pharmacy Inc

ADV-Care Pharmacy Inc is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lineman's Testing Laboratories of Canada Limited

Lineman's Testing Laboratories of Canada Limited is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Remedi

Remedi SeniorCare is a United States-based institutional pharmacy business, serving a growing number of facilities extending from the Mid-Atlantic to the Midwest.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.